Neurotransmitters in Schizophrenia and Other Brain Disorders: Dopamine, Serotonin, and Beyond

Schizophrenia

Complex neurodevelopmental disorder. Dopamine hypothesis: Mesolimbic hyperactivity → positive symptoms (hallucinations, delusions); mesocortical hypoactivity → negative/cognitive symptoms. Serotonin (5-HT2A) modulation explains atypical antipsychotic efficacy. Glutamate (NMDA hypofunction) and GABA are also implicated.

Neurotransmitter Dysregulation Across Disorders

DisorderKey Neurotransmitter Changes
Parkinson'sDopamine ↓ (substantia nigra degeneration)
Alzheimer'sAcetylcholine ↓ (basal forebrain), glutamate excitotoxicity
DepressionSerotonin ↓, norepinephrine ↓, dopamine ↓, BDNF ↓
AnxietySerotonin ↓, GABA ↓, norepinephrine ↑, CRH ↑

Therapeutic Implications

Drugs target these systems: antipsychotics (D2/5-HT2A), levodopa (DA precursor), cholinesterase inhibitors (AChE), SSRIs/SNRIs (5-HT/NE reuptake), benzodiazepines (GABA-A). Precision psychiatry aims to match biology to treatment.

Schizophrenia - Related Articles